Come and meet our experts and find out how GARDP is stimulating R&D for new antimicrobials in the fight against multi-drug resistance

GARDP is the only entity that, in partnership with a small biotech company, has a novel, first-in-class, oral antibiotic in the R&D pipeline to address the rapidly-growing threat of drug-resistant gonorrhoea.

Who you will find and at what at our stand – 92A

If you’re not able to pop by or would like to speak to us, contact Susan Frade, communications lead: sfrade@dndi.org | +41 79 640 0099 | www.gardp.org

Saturday 21
Between 10.30 and 11.30

Ursula Theuretzbacher has been working with GARDP on our antimicrobial memory recovery and exploratory programme, which aims to recover the knowledge, data, and assets of forgotten, abandoned, or withdrawn antibiotics as well as seek new treatments.

Sunday 22
Between 3.30 and 4.30

Mike Sharland is one of the UK and Europe’s leading experts in antimicrobial prescribing, resistance and healthcare associated infection in children. He has an interest in policy initiative to reduce the burden of antimicrobial resistance (AMR) and leads much of GARDP’s work to tackle the death of babies due to sepsis.

Monday 23
Available during the morning break

While significant progress has been made in recent years to improve child health globally, including a 50% reduction in child mortality since 1990, death of babies due to antibacterial resistance is now the main barrier to achieving the sustainable development goal to reduce neonatal mortality.

Sally Ellis leads GARDP’s neonatal sepsis programme which aims to develop treatments for highly drug-resistant infections in babies up to 28 days old with serious bacterial infections. Currently available standard of care is increasingly becoming less effective due to antimicrobial resistance.

Monday 23
Available during the afternoon break

The spread and incidence of gonococcal antimicrobial resistance is rapidly outpacing the development of new medicines. Without action, untreatable gonorrhoea will soon become a reality.

Emilie Alirol leads GARDP’s sexually-transmitted infections programme to develop treatment for gonorrhoea patients with drug-resistant infections by accelerating the development of at least one new drug.
About our experts

Emilie Alirol, GARDP’s STI programme lead
Emilie has a PhD in molecular biology from the University of Geneva and holds a PG diploma in Epidemiology from the London School of Hygiene and Tropical Medicine. Her career started as a Clinical Research Scientist with the Geneva University Hospitals, where she focused on infectious diseases research. After this, she worked as Clinical Trial Manager of an MSF-sponsored trial on Multi-Drug Resistant Tuberculosis (MDR-TB). She has been involved in both therapeutic and diagnostic studies, and has managed several investigator-initiated trials, from phase II to IV.

Sally Ellis, GARDP’s Neonatal Sepsis programme lead
Sally has experience working as a clinical and project manager in the pharmaceutical industry clinical research organizations, as well as the not-for-profit sector. She is a highly experienced clinical trialist, and was instrumental in building and coordinating DND’s clinical portfolio in visceral leishmaniasis. Most recently she worked in the Royal Marsden in the UK to establish the clinical trial unit for all investigator led trials. Sally has significant experience working in resource limited settings and also has a Masters in Global Health Policy from the LSH&TM (2015).

Professor Mike Sharland, Paediatric Infectious Diseases Research at St George’s University of London
Mike is one of the UK and Europe’s leading experts in antimicrobial prescribing, resistance and healthcare associated infection in children. He has an interest in policy initiative to reduce the burden of antimicrobial resistance (AMR) and has been closely involved in the implementation of the National AMR Strategy. He has developed the Paediatric Infectious Diseases Unit at St George’s into a recognised Centre of excellence for clinical care, teaching and research and was appointed Professor of Paediatric Infectious Diseases in November 2010. He is a member of the WHO Essential Medicines List Committee in 2017 helping with the revision of the antibiotic section and is Vice Chair of the PENTA-ID Network.

Ursula Theuretzbacher, PhD, Center for Anti-Infective Agents, Vienna, Austria and consultant to GARDP
Ursula is an expert on antibacterial drug R&D strategies that focus on public health needs and policy initiatives in response to antimicrobial resistance. Her broad therapeutic area expertise includes public funding approaches for antibacterial R&D, initiatives to recover the global pipeline, and strategies to improve the use of antibiotics. She is member of the WHO Priority Pathogen List for R&D project coordinating group, and leading scientist for the Clinical Pipeline analysis at WHO.

Contact Susan Frade, communications lead for more information about GARDP or to speak to one of our experts
sfrade@dndi.org  |  +41 79 640 0099  |  www.gardp.org